Overview
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Background
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Indication
Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
Associated Conditions
- Curarization therapy
- Myasthenia Gravis
- Neuromuscular Blockade
- Postoperative Urinary Retention (POUR)
- Acute Colonic Pseudo-Obstruction
- Post-operative intestinal atony
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2019/01/03 | Not Applicable | UNKNOWN | McGill University Health Centre/Research Institute of the McGill University Health Centre | ||
2018/09/20 | Phase 4 | Completed | |||
2018/09/04 | N/A | Completed | Guangzhou General Hospital of Guangzhou Military Command | ||
2018/07/16 | Phase 4 | Completed | |||
2018/07/11 | Not Applicable | Completed | Ajou University School of Medicine | ||
2018/05/09 | Phase 2 | Completed | Campus Bio-Medico University | ||
2018/05/09 | Phase 2 | UNKNOWN | Campus Bio-Medico University | ||
2018/05/01 | Phase 3 | Completed | |||
2018/04/23 | Phase 4 | UNKNOWN | |||
2017/11/24 | Phase 4 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Dr.Reddys Laboratories Inc | 43598-945 | INTRAVENOUS | 1 mg in 1 mL | 7/7/2022 | |
| Hikma Pharmaceuticals USA Inc. | 0641-6265 | INTRAVENOUS | 1 mg in 1 mL | 4/7/2023 | |
| Exela Pharma Sciences, LLC | 51754-1200 | INTRAVENOUS | 1 mg in 1 mL | 12/31/2023 | |
| Eugia US LLC | 55150-348 | INTRAVENOUS | 0.5 mg in 1 mL | 3/2/2023 | |
| Hikma Pharmaceuticals USA Inc. | 0641-6264 | INTRAVENOUS | 0.5 mg in 1 mL | 4/7/2023 | |
| Medical Purchasing Solutions, LLC | 71872-7322 | INTRAVENOUS | 1 mg in 1 mL | 3/5/2024 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||